modafinil and Depressive Disorder

modafinil has been researched along with Depressive Disorder in 24 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Depressive Disorder: An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.

Research

Studies (24)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

1 Week Delayed Recall Logical Memory

Higher scores reflect greater recall of Wechsler Memory Scale (WMS) Story B content assessed one week after last rehearsal. Possible scores range from 0 to 25. (NCT02376257)
Timeframe: Week 2 and Week 3

1 Week Delayed Recall of Emotional Story Items

1 Week Delayed Recall of a Threat-Related Story. Scores can range from 0 to 74, with higher scores reflect greater memory for story items. (NCT02376257)
Timeframe: Week 2 and Week 3

Digits Backward

The examiner reads a list of digits and asks that each digit be read backwards. The score is the total number of trials completed correctly; scores range from 0 to 16. Higher scores indicate better performance. (NCT02376257)
Timeframe: Baseline, Week 1, Week 2, Week 3

Immediate Memory Measured by the Hopkins Verbal Learning Task

The Hopkins Verbal Learning Test (HVLT) consists of a 12-item word list, composed of four words from each of the three semantic categories. The patient's free recall of the list is recorded. The same procedure is repeated for two more trials. The total recall score for the third trial was used as the recorded score and ranged from a minimum of zero to a maximum of 12 correct answers. (NCT02376257)
Timeframe: Baseline, Week 1, Week 2, Week 3

Immediate Recall of Emotional Story Items

Immediate recall score of items from the Emotional Story presentation. Scores can range from 0 to 74, with higher scores reflect greater memory for story items. (NCT02376257)
Timeframe: Week 1, Week 2, Week 3

Logical Memory Immediate Recall

Immediate Story Recall from the Wechsler Memory Scale Story B. Higher scores reflect greater recall of the story material from the previous week. Possible scores range from 0 to 25. (NCT02376257)
Timeframe: Week 1, Week 2, Week 3

Recall of Cognitive Therapy Content

A modified Cognitive Therapy Awareness Scale (CTAS) was used to assess delayed memory for cognitive therapy content from the computerized CBT. Higher scores indicate better memory for CBT skills. Scores range from 0 to 40. (NCT02376257)
Timeframe: Week 2 and Week 3

Skills of Cognitive Therapy

This measure assesses the self-reported use of skills from cognitive therapy. Scores can range from 8 to 40, and higher scores indicate greater use. (NCT02376257)
Timeframe: Week 2 and Week 3

BDI Score

Self-reported depression: mean change on Beck Depression Index (BDI-II) assessed weekly during the 12 week medication phase. If the week12 measure was not available, the last observation was carried forward. 0 indicates no depression, 63 is the maximum indicating severe depression. (NCT00469508)
Timeframe: From baseline to end of treatment period (week 12).

Clean Urine Drug Screen

Urine samples, collected thrice weekly, were tested for metabolites of MA using radioimmunoassay. Each subject had a possible of 36 urine drug screens to provide during the 12 weeks of medication. An aggregate measure of urine drug screen results was calculated - the Treatment Effectiveness Score (TES) - which is the average of the sum of MA-free urine specimens provided during the treatment period by participants in each treatment condition. (NCT00469508)
Timeframe: From randomization to end of week 12

Retention

The number of persons who completed the medication phase of the trial (12 weeks of medication). (NCT00469508)
Timeframe: 12 weeks

VAS Score

To measure methamphetamine craving, mean change in craving based on visual analog scale (VAS) from 0 (not at all) to 100 (extremely) from baseline to the last week of observation during the 12 week treatment period. The last observation was carried forward if not available during week 12. (NCT00469508)
Timeframe: baseline and last observation during the 12 week treatment period

CD4 Cell Count

CD4 cell count is a laboratory marker providing an indication of immune functioning. Blood was drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >= 100 cells. A higher number is associated with better immune functioning. (NCT00118378)
Timeframe: Measured at baseline and Week 4

Fatigue Severity Scale (FSS)

The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9 to 63, with a higher value indicating greater impairment due to fatigue. (NCT00118378)
Timeframe: Measured at baseline and Week 4

HIV RNA Viral Load

"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50-100,000 copies), this measure is presented in log10. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00118378)
Timeframe: Measured at baseline and Week 4

Role Function Scale Outcome

The Role Function Scale includes 10 items drawn from the Short Form 36-item Health Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10 to 50. (NCT00118378)
Timeframe: Measured at baseline and Week 4

CD4 Cell Count

Cd4 cell count is a laboratory marker providing an indication of immune system functioning. Blood samples were drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >=100 cells. A higher number is associated with better immune functioning. (NCT00737204)
Timeframe: Measured at baseline and Week 4

Fatigue Severity Scale(FSS) Outcome

The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9-63, with a higher score indicating greater impairment due to fatigue. (NCT00737204)
Timeframe: Measured at baseline and Weeks 4

HIV Viral Load

"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50 - 100,000 copies), this measure is transformed to log10 values. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00737204)
Timeframe: Measured at baseline and Week 4

Role Function Scale

The Role Function Scale includes 10 items drawn from the Short Form 36-item Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10-50. (NCT00737204)
Timeframe: Measured at Baseline and Week 4

Reviews

7 reviews available for modafinil and Depressive Disorder

Trials

8 trials available for modafinil and Depressive Disorder

Other Studies

9 other studies available for modafinil and Depressive Disorder